WFRF:(Tokgözoglu Lale)
Sökning: WFRF:(Tokgözoglu Lale) > (2020-2023) > Evaluation of lipop...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
- Catapano, Alberico LIRCCS MultiMedica, Sesto San Giovanni, MI, Italy; Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy. Electronic address alberico.catapano@multimedica.it (författare)
Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network
- Artikel/kapitelEngelska2023
Förlag, utgivningsår, omfång ...
- Elsevier,2023
- printrdacarrier
Nummerbeteckningar
- LIBRIS-ID:oai:DiVA.org:liu-202844
- https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-202844URI
- https://doi.org/10.1016/j.atherosclerosis.2023.02.007DOI
Kompletterande språkuppgifter
- Språk:engelska
- Sammanfattning på:engelska
Ingår i deldatabas
- SwePubSwePub
Klassifikation
Anmärkningar
- Background and aims: The European Atherosclerosis Society (EAS) Lipid Clinics Network promoted a survey in order to identify and understand how and when lipoprotein(a) [Lp(a)] is tested and clinically evaluated in lipid clinics throughout Europe, and the challenges that may prevent evaluation from being carried out. Methods: This survey was divided into three areas of inquiry: background and clinical setting information of clinicians, questions for doctors who claimed not to measure Lp(a), in order to understand what were the reasons for not ordering the test, and questions for doctors who measure Lp(a), to investigate the use of this value in the management of patients. Results: A total of 151 centres clinicians filled in the survey, out of 226 invited. The proportion of clinicians who declare to routinely measure Lp(a) in clinical practice was 75.5%. The most common reasons for not ordering the Lp(a) test were the lack of reimbursement or of treatment options, the non-availability of Lp(a) test, and the high cost of performing the laboratory test. The availability of therapies targeting this lipoprotein would result in a greater propensity of clinicians to start testing Lp(a). Among those who declared to routinely measure Lp(a), the Lp(a) measurement is mostly requested to further stratify patients’ cardiovascular risk, and half of them recognized 50 mg/dL (approx. 110 nmol/L) as the threshold for increased cardiovascular risk due. Conclusions: These results warrant for a great deal of effort from scientific societies to address the barriers that limit the routine use of the measurement of Lp(a) concentration and to recognise the importance of Lp(a) as a risk factor.
Ämnesord och genrebeteckningar
- MEDICIN OCH HÄLSOVETENSKAP Hälsovetenskap Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi hsv//swe
- MEDICAL AND HEALTH SCIENCES Health Sciences Public Health, Global Health, Social Medicine and Epidemiology hsv//eng
- Cardiovascular risk; Clinical evaluation; Clinicians; Lipoprotein(a)
Biuppslag (personer, institutioner, konferenser, titlar ...)
- Tokgözoglu, LaleDepartment of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey (författare)
- Banach, MaciejDepartment of Preventive Cardiology and Lipidology, Medical University of Lodz, Lodz, Poland; Cardiovascular Research Centre, University of Zielona Gora, Gora, Poland (författare)
- Gazzotti, MartaSISA Foundation, Milan, Italy (författare)
- Olmastroni, ElenaEpidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy (författare)
- Casula, ManuelaIRCCS MultiMedica, Sesto San Giovanni, MI, Italy; Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy (författare)
- Ray, Kausik KImperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, London, UK (författare)
- Muhr, ThomasLinköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Kardiologiska kliniken US,Lipid Clinics Network Group(Swepub:liu)thomu80 (bidragsgivare)
- IRCCS MultiMedica, Sesto San Giovanni, MI, Italy; Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy. Electronic address alberico.catapano@multimedica.itDepartment of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey (creator_code:org_t)
Sammanhörande titlar
- Ingår i:Atherosclerosis: Elsevier370, s. 5-110021-91501879-1484
Internetlänk
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Catapano, Alberi ...
- Tokgözoglu, Lale
- Banach, Maciej
- Gazzotti, Marta
- Olmastroni, Elen ...
- Casula, Manuela
- visa fler...
- Ray, Kausik K
- Muhr, Thomas
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Hälsovetenskap
- och Folkhälsovetensk ...
- Artiklar i publikationen
- Atherosclerosis
- Av lärosätet
- Linköpings universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
